NCT02601248View on ClinicalTrials.gov

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 29, 2016

Study Completion Date

May 31, 2016

Conditions
Cancer
Interventions
DRUG

Theliatinib

Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily

Trial Locations (1)

300060

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT02601248 - Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | Biotech Hunter | Biotech Hunter